Alpha Tau Medical Ltd., (Israel) presented preliminary clinical results of its alpha-radiation-based brachytherapy (Alpha DaRT) at ASTRO (American Society for Therapeutic Radiation Oncology) on October 23 in San Antonio, Texas, USA. HekaBio has partnered with Alpha Tau Medical to develop and commercialize the Alpha DaRT cancer treatment for solid tumors in Japan.
The clinical results carried out in Israel were from 15 subjects who completed follow-up for 30-45 days, resulting in an overall response rate of 100% and a complete response rate over 73%. Some of the subjects were elderly patients who were medically unfit for surgery or failed previous external beam radiation. It was demonstrated that the Alpha DaRT can be administered safely under local anesthesia in an outpatient setting for all of the patients, including the given sensitive cases.
Please refer to the attached poster for the content of the clinical trial.
About Alpha Tau Medical LTD
Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumor cancers. The Alpha DaRT technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari in 2003 at Tel Aviv University. The company strives “to enable a cancer treatment that destroys tumors while sparing healthy tissue to save the lives of millions of patients around the world.” (Alpha Tau Medical, Mission Statement)
For more information, please visit http://www.alphatau.com/
About Alpha DaRT
The Alpha DaRT has several important advantages:
• Highly potent and conformal
• Proven efficacy for all solid tumors tested
• Stimulates anti-tumor immune response
• Low toxicity, no known negative systemic effects
• Effective regardless of tumor oxygen level
• Short half-life – quick clinical outcome
• Single-session treatment
• Enables combination with other therapies or reapplication
• Disposable applicators - does not require capital equipment or special shielding